Phaxiam: 'remarkable' performance against bacteria

(CercleFinance.com) - Phaxiam Therapeutics announced last night that, at a recent one-day meeting with international experts, it had presented results showing that its phages had demonstrated 'remarkable' performance against clinical bacterial strains.


The biopharmaceutical company - which specializes in the development of treatments for resistant bacterial infections - took the opportunity to describe the regulatory and technical-scientific framework for the development of its phage test, as well as the lessons learned from the analysis of over 398 clinical strains.

Phaxiam, whose product candidates are now used in compassionate clinical practice, reports that up to the first quarter of 2024, it had observed 98.7% of strains sensitive to at least one of the anti-S. aureus phages in bacterial infections caused by staphylococcus aureus.

In bacterial infections caused by Pseudomonas aeruginosa, the sensitivity observed up to the 1st half of 2024 stood at 71.3% of strains sensitive to at least one of the anti-P-aeruginosa phages, says Phaxiam.

On the Paris stock exchange, Phaxiam's share price fell by over 2% on Tuesday following the release of these data, bringing its year-to-date decline to 63%.

Copyright (c) 2024 CercleFinance.com. All rights reserved.